Wikipedia -WSS

Wikipedia

author：fashion 2025-09-06 03:55:47 - browse：84

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Lab trade group sues FDA to halt regulation of lab

WSS

Prosthetic arm enables patients to feel the objects they grip

EPA limits use of carcinogenic gas for sterilizing medical devices

What will save rural psychiatry services? Higher Medicaid payments

John Green on his newest strategy for fighting tuberculosis

Medicare coverage of Wegovy, once blocked, now looks possible

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Activists slam private health insurers over coverage restrictions

Amid AI frenzy, a top HHS official's quest to create safeguards

The cancer drug shortage isn’t new — and neither are the solutions

iTeos Therapeutics debuts first data on TIGIT

Activists slam private health insurers over coverage restrictions

Latest bird flu infection made farmworker sicker than earlier cases

Peter Hotez and the public health issue of online harassment

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Affirmative action in medical school literally saved lives

Latest bird flu infection made farmworker sicker than earlier cases

hotspot

Lab trade group sues FDA to halt regulation of lab

Stigma and the return of syphilis

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Medicare coverage of Wegovy, once blocked, now looks possible

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

hotspot

hotspot

knowledge

Wikipedia